Queen Square Centre for Neuromuscular Diseases


Arimoclomol eases IBM in small trial

1 January 2014

Arimoclomol showed promise as a treatment for the most common type of inflammatory myopathy in adults over age 50 in a 1-year, phase IIa, "proof-of-concept" study.

Not only was the novel oral agent "well tolerated," which was the study's main objective to assess, but it also showed early signs that it could be effective in the treatment of patients with sporadic inclusion body myositis (IBM). Indeed, there was a trend toward slower deterioration in physical function and muscle strength for arimoclomol when compared against placebo at 8 months' follow-up.

Click here to view the full EULAR 2013 Congress report